These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 20082624

  • 1. Glipizide controlled-release tablets, with or without acarbose, improve glycaemic variability in newly diagnosed Type 2 diabetes.
    Bao YQ, Zhou J, Zhou M, Cheng YJ, Lu W, Pan XP, Tang JL, Lu HJ, Jia WP.
    Clin Exp Pharmacol Physiol; 2010 May; 37(5-6):564-8. PubMed ID: 20082624
    [Abstract] [Full Text] [Related]

  • 2. Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea.
    Goldstein BJ, Pans M, Rubin CJ.
    Clin Ther; 2003 Mar; 25(3):890-903. PubMed ID: 12852706
    [Abstract] [Full Text] [Related]

  • 3. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS, Lin SD, Lee WJ, Su SL, Lee IT, Tu ST, Tseng YH, Lin SY, Sheu WH.
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [Abstract] [Full Text] [Related]

  • 4. Glycemic variability in insulin treated type 2 diabetes with well-controlled hemoglobin A1c and its response to further treatment with acarbose.
    Su JB, Wang XQ, Chen JF, Wu G, Jin Y.
    Chin Med J (Engl); 2011 Jan; 124(1):144-7. PubMed ID: 21362322
    [Abstract] [Full Text] [Related]

  • 5. Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy: A Placebo-Controlled Trial.
    Derosa G, Franzetti I, Querci F, D'Angelo A, Maffioli P.
    Pharmacotherapy; 2015 Nov; 35(11):983-90. PubMed ID: 26598090
    [Abstract] [Full Text] [Related]

  • 6. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM).
    Abraira C, Henderson WG, Colwell JA, Nuttall FQ, Comstock JP, Emanuele NV, Levin SR, Sawin CT, Silbert CK.
    Diabetes Care; 1998 Apr; 21(4):574-9. PubMed ID: 9571345
    [Abstract] [Full Text] [Related]

  • 7. Nateglinide and acarbose are comparably effective reducers of postprandial glycemic excursions in chinese antihyperglycemic agent-naive subjects with type 2 diabetes.
    Zhou J, Li H, Zhang X, Peng Y, Mo Y, Bao Y, Jia W.
    Diabetes Technol Ther; 2013 Jun; 15(6):481-8. PubMed ID: 23631607
    [Abstract] [Full Text] [Related]

  • 8. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL, Figgitt DP.
    Pharmacoeconomics; 2004 Jun; 22(6):389-411. PubMed ID: 15099124
    [Abstract] [Full Text] [Related]

  • 9. Different clinical prognostic factors are associated with improved glycaemic control: findings from MARCH randomized trial.
    Han J, Yu H, Tu Y, Pang J, Liu F, Bao Y, Yang W, Jia W.
    Diabet Med; 2017 Apr; 34(4):490-499. PubMed ID: 27151271
    [Abstract] [Full Text] [Related]

  • 10. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group.
    Simonson DC, Kourides IA, Feinglos M, Shamoon H, Fischette CT.
    Diabetes Care; 1997 Apr; 20(4):597-606. PubMed ID: 9096986
    [Abstract] [Full Text] [Related]

  • 11. The beneficial effect of α-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: preliminary data.
    Lin SD, Wang JS, Hsu SR, Sheu WH, Tu ST, Lee IT, Su SL, Lin SY, Wang SY, Hsieh MC.
    J Diabetes Complications; 2011 Apr; 25(5):332-8. PubMed ID: 21813293
    [Abstract] [Full Text] [Related]

  • 12. Saxagliptin is similar in glycaemic variability more effective in metabolic control than acarbose in aged type 2 diabetes inadequately controlled with metformin.
    Wang MM, Lin S, Chen YM, Shu J, Lu HY, Zhang YJ, Xie RY, Zeng LY, Mu PW.
    Diabetes Res Clin Pract; 2015 Jun; 108(3):e67-70. PubMed ID: 25841300
    [Abstract] [Full Text] [Related]

  • 13. Effect of acarbose on additional insulin therapy in type 2 diabetic patients with late failure of sulphonylurea therapy.
    Standl E, Baumgartl HJ, Füchtenbusch M, Stemplinger J.
    Diabetes Obes Metab; 1999 Jul; 1(4):215-20. PubMed ID: 11228756
    [Abstract] [Full Text] [Related]

  • 14. Factors that influence the efficacy of acarbose and metformin as initial therapy in Chinese patients with newly diagnosed type 2 diabetes: a subanalysis of the MARCH trial.
    Zhang J, Wang N, Xing X, Yang Z, Wang X, Yang W.
    Curr Med Res Opin; 2016 Jul; 32(4):713-9. PubMed ID: 26714411
    [Abstract] [Full Text] [Related]

  • 15. Glycemic excursions are positively associated with HbA1c reduction from baseline after treatment with acarbose in patients with type 2 diabetes on metformin monotherapy.
    Wang JS, Lee IT, Lee WJ, Lin SD, Su SL, Tu ST, Tseng YH, Lin SY, Sheu WH.
    J Diabetes; 2017 Mar; 9(3):248-255. PubMed ID: 27043224
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Glargine insulin/gliclazide MR combination therapy is more effective than premixed insulin monotherapy in Chinese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs.
    Zhou J, Zheng F, Guo X, Yang H, Zhang M, Tian H, Guo L, Li Q, Mo Y, Jia W.
    Diabetes Metab Res Rev; 2015 Oct; 31(7):725-33. PubMed ID: 25952634
    [Abstract] [Full Text] [Related]

  • 18. A prospective, parallel group, open-labeled, comparative, multi-centric, active controlled study to evaluate the safety, tolerability and benefits of fixed dose combination of acarbose and metformin versus metformin alone in type 2 diabetes.
    Jayaram S, Hariharan RS, Madhavan R, Periyandavar I, Samra SS.
    J Assoc Physicians India; 2010 Nov; 58():679-82, 687. PubMed ID: 21510461
    [Abstract] [Full Text] [Related]

  • 19. Comparative efficacy of a once-daily controlled-release formulation of glipizide and immediate-release glipizide in patients with NIDDM.
    Berelowitz M, Fischette C, Cefalu W, Schade DS, Sutfin T, Kourides IA.
    Diabetes Care; 1994 Dec; 17(12):1460-4. PubMed ID: 7882817
    [Abstract] [Full Text] [Related]

  • 20. Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study.
    Madsbad S, Kilhovd B, Lager I, Mustajoki P, Dejgaard A, Scandinavian Repaglinide Group.
    Diabet Med; 2001 May; 18(5):395-401. PubMed ID: 11472451
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.